Villicent Uy
Primary Care · New York, NYNPI 1134497902
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 28.2% of the total. Reporting peaked in 2022 at $665 and has fallen 90.2% since, to $65 in 2025.
Across 83 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$511
- GSK$228
- Bausch Health US, LLC$184
- Pfizer$142
- Axsome Therapeutics, Inc.$121
- Esperion Therapeutics, Inc.$67
- plus $558 from 14 others
What the payments were for
- Food & beverage$1,811100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $511 |
| GSK | 9 | $228 |
| Bausch Health US, LLC | 10 | $184 |
| Pfizer | 6 | $142 |
| Axsome Therapeutics, Inc. | 4 | $121 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Antares Pharma, Inc. | 3 | $66 |
| Philips North America LLC | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Acerus Pharmaceuticals Corporation | 3 | $53 |
| Eisai Inc. | 3 | $48 |
| Baxter Healthcare | 1 | $42 |
| Almatica Pharma LLC | 2 | $41 |
| Lilly USA, LLC | 2 | $41 |
| Amgen | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Bayer | 1 | $20 |
| AstraZeneca | 1 | $20 |
How this compares
$1,811 in reported general payments places this provider in the 80th percentile of 239 primary care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zolpidem Tartrate | 73 | $748 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $433 |
| Alprazolam | 51 | $419 |
| Levothyroxine Sodium | 23 | $381 |
| Oxycodone Hcl | 19 | $347 |
| Rosuvastatin Calcium | 26 | $347 |
| Atorvastatin Calcium | 12 | $257 |
| Olmesartan Medoxomil | 12 | $190 |
| Pantoprazole Sodium | 18 | $154 |
| Amlodipine Besylate | 14 | $137 |
| Gabapentin | 13 | $91 |
| Metformin Hcl ErMetformin Hcl | 13 | $18 |
Paid to pharmacies, not to this prescriber.
Other primary care in New York
- Dorothy KleinertNew York$27K
- Lisa PlanetaNew York$6K
- Erica StumpfNew York$4K
- Eunae KoNew York$4K
- Mona AboulnajaNew York$2K
- Kristl RamjattanNew York$2K
- Carl GastanesNew York$2K
- Yan Fon MeiNew York$2K
- Kathryn DowlingNew York$2K
- Stephanie KhanForest Hills$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.